Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors. Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.

Topics will include:

  • Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
  • Signatera clinical data in early and late stage solid tumors
  • Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout

Featured Speaker

Alexey Aleshin, M.D., M.B.A

Senior Medical Director, Oncology
Natera

Dr. Alexey Aleshin has led the oncology clinical development efforts at Natera, Inc. since 2018. He is a subject expert in novel clinical trials that utilize ctDNA for patient enrichment and treatment response assessment. He received a B.A. in Statistics from UC Berkeley and his M.D. / M.B.A. degrees at UCLA. He completed his clinical training in internal medicine and hematology / oncology at Stanford University.

NOW AVAILABLE ON-DEMAND

Register now for this webinar